Outcome with different treatment approaches in older patients with ALL
| Approach . | Reference (s) . | Age range (y) . | Studies (N) . | Patients (N) . | CR* . | Early death* . | Survival† . |
|---|---|---|---|---|---|---|---|
| Population-based studies | 2, 15, 26, 27 | >65 | 4 | n.r. | 40%‡ | n.r. | 6%-30% |
| Palliative treatment | 29-31, 33 | 60-91 | 4 | 94 | 43% (34%-53%) | 24% (18%-42%) | 7 (3-10) mo |
| Intensive chemotherapy designed for adult ALL without focus on older patients | 17, 32, 34-43 | 60-92 | 12 | 519 | 56% (40%-81%) | 23% (6%-42%) | 14% (3%-29%) |
| Approach . | Reference (s) . | Age range (y) . | Studies (N) . | Patients (N) . | CR* . | Early death* . | Survival† . |
|---|---|---|---|---|---|---|---|
| Population-based studies | 2, 15, 26, 27 | >65 | 4 | n.r. | 40%‡ | n.r. | 6%-30% |
| Palliative treatment | 29-31, 33 | 60-91 | 4 | 94 | 43% (34%-53%) | 24% (18%-42%) | 7 (3-10) mo |
| Intensive chemotherapy designed for adult ALL without focus on older patients | 17, 32, 34-43 | 60-92 | 12 | 519 | 56% (40%-81%) | 23% (6%-42%) | 14% (3%-29%) |
Adapted from Gökbuget.1
n.r., not reported.
Weighted means and range from cited studies for CR rates, early death rates, and survival.
Weighted means and ranges for survival probability at 2 or more years as reported in the cited studies or median survival time and ranges, respectively.
From Toft et al.27